D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target

Benzinga · 5d ago
D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.